Amoy Diagnostics Co Ltd (300685.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE1000034D3
Amoy Diagnostics Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.11 bn CNY | 1.20 bn CNY |
| Gross profit | 927.61 m CNY | 989.22 m CNY |
| Operating income | 292.98 m CNY | 417.66 m CNY |
| EBIT | 291.57 m CNY | 412.85 m CNY |
| Net income | 254.86 m CNY | 357.89 m CNY |
| Diluted EPS – continuing operations | 0.64 CNY | 0.90 CNY |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a comprehensive genomic profiling assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; and AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel solutions. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.
More stocks
- TLG Immobilien (TLG.HM)
- Wenzhou Yihua Connector Co Ltd (002897.SZ)
- Arendals Fossekompani ASA (AFK.OL)
- Taboola.com Ltd. (TBLA)
- Chengdu Yunda Technology Co Ltd (300440.SZ)
- NAPCO SECURITY TECHNOLOGIES, INC (NSSC)
- Grupo KUO S.A.B. de C.V (KUOB.MX)
- Lampsa Hellenic Hotels SA (LAMPS.AT)
- Amphastar Pharmaceuticals, Inc. (AMPH)
- ARTIVION, INC. (AORT)
- PT Jhonlin Agro Raya Tbk (JARR.JK)
- Lanxess (LXS.DE)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.